Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

United Kingdom: Programs May Curb Hepatitis C in Drug Users

July 28, 2011

A recent report offers fresh evidence that needle-exchange programs (NEPs) and opiate substitution therapy (OST) can reduce injection drug users' (IDUs) odds of contracting hepatitis C virus (HCV).

Senior researcher Matthew Hickman, a professor of public health at the University of Bristol, and colleagues pooled the results of six previous studies of UK programs (based in Birmingham, Bristol, Glasgow, Leeds, London, and Wales). The results showed that IDUs with the highest coverage of NEPs were about half as likely to contract HCV as others.

Among the group of IDUs who said they accessed enough clean needles for all their injections, slightly less than 4 percent tested HCV-positive during the studies, which lasted as long as one year. This compares to 7 percent for IDUs who said they did not receive clean needles for all their injections.

Advertisement
Among IDUs who were currently on OST, the rate of new HCV infection was 3 percent, compared to 7 percent for those not on OST.

For IDUs who were participating in NEPs and OST, the new HCV infection rate was just 2 percent.

The authors noted the study's limitations, including that its findings are based on small numbers and concerned only UK programs. Still, Hickman believes the work fills some knowledge gaps relating to how well IDU programs are working.

One question for future research, Hickman said, is whether treating HCV infection in IDUs helps reduce onward transmission.

The authors concluded, "There is good evidence that uptake of opiate substitution therapy and high coverage of needle and syringe programs can substantially reduce the risk of HCV transmission among IDUs. Research is required now on whether the scaling-up of intervention exposure can reduce and limit HCV prevalence in this population."

The study, "The Impact of Needle and Syringe Provision and Opiate Substitution Therapy on the Incidence of Hepatitis C Virus in Injecting Drug Users: Pooling of UK Evidence," was published in Addiction (2011;doi:10.1111/j.1360-0442.2011.03515.x).

Back to other news for July 2011

Adapted from:
Reuters Health
06.29.2011; Amy Norton


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More News on HIV/AIDS in the United Kingdom
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement